首页> 美国卫生研究院文献>BMJ Open Access >Extended report: Golimumab a human antibody to tumour necrosis factor α given by monthly subcutaneous injections in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

【2h】

Extended report: Golimumab a human antibody to tumour necrosis factor α given by monthly subcutaneous injections in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

机译：扩展报告：尽管甲氨蝶呤治疗但在活动性类风湿性关节炎中通过每月皮下注射给予戈利木单抗（一种通过每月皮下注射给予的一种抗肿瘤坏死因子α的人抗体）：GO-FORWARD研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective:The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy.

机译：目的：III期GO-FORWARD研究检查了甲氨蝶呤疗法治疗活动性类风湿关节炎（RA）的戈利木单抗的疗效和安全性。

著录项

期刊名称 BMJ Open Access
作者
E C Keystone; M C Genovese; L Klareskog; E C Hsia; S T Hall; P C Miranda; J Pazdur; S-C Bae; W Palmer; J Zrubek; M Wiekowski; S Visvanathan; Z Wu; M U Rahman;
展开▼
作者单位

展开▼
年(卷),期 -1(68),6
年度 -1
页码 789–796
总页数 8
原文格式 PDF
正文语种
中图分类
关键词
入库时间 2022-08-21 11:00:07

相似文献

外文文献
专利

1. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. [J] . Keystone EC, Genovese MC, Klareskog L Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2009,第6期

机译：尽管甲氨蝶呤治疗，但在活动性类风湿性关节炎中，通过每月皮下注射给予戈利木单抗的人类肿瘤坏死因子{α}抗体：GO-FORWARD研究。
2. Erratum: Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [J] . li id=au1Paul Emery li id=au2Roy M. Fleischmann li id=au3Larry W. Moreland li id=au4Elizabeth C. Hsia li id=au5Ingrid Strusberg li id=au6Patrick Durez li id=au7Peter Nash li id=au8Eric Jason B. Amante li id=au9Melvin Churchill li id=au10Won Park li id=au11Bernardo Antonio Pons-Estel li id=au12Mittie K. Doyle li id=au13Sudha Visvanathan li id=au14Weichun Xu li id=au15Mahboob U. Rahman Arthritis & Rheumatism . 2010,第9期

机译：勘误：Golimumab，一种人类抗肿瘤坏死因子单克隆抗体，每隔四周皮下注射一次未接受甲氨蝶呤的活动性类风湿性关节炎患者：三期，多中心，随机，双盲，安慰剂治疗二十三周的结果氨甲蝶呤前戈利木单抗作为早期治疗类风湿关节炎的一线治疗的对照研究
3. Golimumab, a Human Anti-Tumor Necrosis Factor alpha Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis (vol 60, pg 2272, 2009) [J] . Emery Arthritis and Rheumatism . 2010,第9期

机译：Golimumab是一种人类抗肿瘤坏死因子α单克隆抗体，每四周一次皮下注射纯净甲氨蝶呤的活动性类风湿性关节炎患者，III期，多中心，随机，双盲，安慰剂对照研究的二十四周结果甲氨tre呤之前戈利木单抗作为早期治疗类风湿关节炎的一线治疗方法的研究（第60卷，第2272页，2009年）
4. Affinity purification of recombinant human tumour necrosis factor beta (rhtnf-beta) by complementary peptide P59 and its binding studies [C] . K.C.Loh, Lu Zheng, Miranda G.S.Yap, Asia-Pacific biochemical engineering conference;APBIOCHEC'97 . 1997

机译：互补肽P59亲和纯化重组人肿瘤坏死因子β（rhtnf-beta）及其结合研究
5. Pro-inflammatory T helper cells in rheumatoid arthritis: Influence of tumour necrosis factor inhibition. [D] . Aerts, Nicolaas. 2010

机译：类风湿关节炎中的促炎性T辅助细胞：肿瘤坏死因子抑制的影响。
6. Extended report: Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study [O] . Josef S Smolen, Jonathan Kay, Eric L Matteson, -1

机译：扩展报告：了解戈利木单抗联合氨甲蝶呤在活动类风湿性关节炎患者中终止先前的抗肿瘤坏死因子治疗的疗效：GO-AFTER研究的事后分析
7. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study [O] . Keystone, E C, Genovese, M C, Klareskog, L, 2008

机译：甲氨蝶呤疗法治疗活动性类风湿性关节炎，通过每月皮下注射给予人类抗肿瘤坏死因子α抗体戈利木单抗：GO-FORWARD研究

相关主题

Extended report: Golimumab a human antibody to tumour necrosis factor α given by monthly subcutaneous injections in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

摘要

著录项

相似文献

相关主题

期刊订阅